1. Market Research
  2. > Enterobacteriaceae Infections - Pipeline Review, H2 2013

Enterobacteriaceae Infections - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 46 pages

Enterobacteriaceae Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Enterobacteriaceae Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Enterobacteriaceae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterobacteriaceae Infections. Enterobacteriaceae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Enterobacteriaceae Infections.
- A review of the Enterobacteriaceae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Enterobacteriaceae Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Enterobacteriaceae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Enterobacteriaceae Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Enterobacteriaceae Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Enterobacteriaceae Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Enterobacteriaceae Infections 7
Enterobacteriaceae Infections Therapeutics under Development by Companies 9
Mid Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Enterobacteriaceae Infections Therapeutics - Products under Development by Companies 13
Companies Involved in Enterobacteriaceae Infections Therapeutics Development 14
Achaogen Inc. 14
Trana Discovery, Inc. 15
Da Volterra 16
Enterobacteriaceae Infections - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
plazomicin - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
RX-04 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
RX-P792 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Gram Negative Antibacterial Programs - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Metallo-Beta-Lactamase Inhibitors - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
DAV-121 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
NOSO-74 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
NAB-741 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
NAB-7061 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Enterobacteriaceae Infections Therapeutics - Drug Profile Updates 36
Enterobacteriaceae Infections Therapeutics - Discontinued Products 39
Enterobacteriaceae Infections Therapeutics - Dormant Products 40
Enterobacteriaceae Infections - Product Development Milestones 41
Featured News and Press Releases 41
Sep 23, 2013: Achaogen Announces Agreement With FDA on a Special Protocol Assessment for a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) 41
Apr 24, 2013: Achaogen Receives $60m Contract Option From BARDA For Clinical Development Of Plazomicin 41
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CXA-201 At ICAAC 2012 42
May 03, 2011: Rib-X Pharma To Present Three Posters On Its RX-04 Development Program At 21st ECCMID/ 27th ICC 42
Jan 06, 2011: NovaBay Reports Activity Of NVC-422 Against Deadly Superbug Producing NDM-1 43
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46



List of Tables

Number of Products Under Development for Enterobacteriaceae Infections, H2 2013 7
Products under Development for Enterobacteriaceae Infections - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Achaogen Inc., H2 2013 14
Trana Discovery, Inc., H2 2013 15
Da Volterra, H2 2013 16
Assessment by Monotherapy Products, H2 2013 17
Assessment by Stage and Route of Administration, H2 2013 19
Assessment by Stage and Molecule Type, H2 2013 21
Enterobacteriaceae Infections Therapeutics - Drug Profile Updates 36
Enterobacteriaceae Infections Therapeutics - Discontinued Products 39
Enterobacteriaceae Infections Therapeutics - Dormant Products 40



List of Figures

Number of Products under Development for Enterobacteriaceae Infections, H2 2013 7
Products under Development for Enterobacteriaceae Infections - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 11
Discovery and Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 17
Assessment by Route of Administration, H2 2013 18
Assessment by Stage and Route of Administration, H2 2013 19
Assessment by Molecule Type, H2 2013 20
Assessment by Stage and Molecule Type, H2 2013 21



Companies Mentioned

Achaogen Inc.
Trana Discovery, Inc.
Da Volterra

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.